Vertex Pharmaceuticals Inc (VRTX)

[surf1944]

Vertex Pharmaceuticals Announces Pricing of its Public Offering of Common Stock
Thursday September 18, 8:46 am ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in aggregate gross proceeds of approximately $191.3 million. Vertex has granted the underwriter an option to purchase up to an additional 1,125,000 shares of Vertex common stock on the same terms and conditions.

Goldman, Sachs & Co. is acting as the sole book-runner for the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. An automatically effective shelf registration statement relating to the shares of common stock Vertex intends to sell has been filed with the Securities and Exchange Commission. Any offer of shares of common stock will be made only by means of a prospectus, including a prospectus supplement, forming a part of the automatically effective shelf registration statement. A copy of the prospectus for the offering can be obtained from Goldman, Sachs & Co.’s prospectus department, at 85 Broad Street, New York, New York 10004, Fax: [phone] or Email at [e-mail].